Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bimiralisib suppresses proliferation and migration of gastric cancer cells <i>via</i> PI3K/mTOR pathway inhibition.

The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology·2026
Same author

Dual Roles of hABCB1 in Drug Resistance and Immune Evasion: Implications for Lung Cancer Therapy.

ACS omega·2026
Same author

From Orange to Oncology: Anti-Inflammatory and Anti-Cancer Mechanisms of Sinensetin.

Cells·2026
Same author

JAK2 Inhibition Augments the Anti-Proliferation Effects by AKT and MEK Inhibition in Triple-Negative Breast Cancer Cells.

International journal of molecular sciences·2025
Same author

Therapeutic implication of oxidative stress-induced growth inhibitor 1 (OSGIN1) in cancer.

Oncogene·2025
Same author

Anti-proteolytic regulation of KRAS by USP9X/NDRG3 in KRAS-driven cancer development.

Nature communications·2025

Related Experiment Video

Updated: Jul 16, 2025

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
03:37

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

798

Beta-Transducin Repeats-Containing Proteins as an Anticancer Target.

Dong Joon Kim1,2,3,4, Yong Weon Yi2,5, Yeon-Sun Seong2,5

  • 1Department of Microbiology, College of Medicine, Dankook University, Cheonan-si 31116, Chungcheongnam-do, Republic of Korea.

Cancers
|September 9, 2023
PubMed
Summary

Beta-transducin repeat-containing proteins (β-TrCPs) regulate key cellular processes and are linked to cancer. This review analyzes how β-TrCPs are regulated, identifying knowledge gaps for future therapeutic strategies.

Keywords:
anticancerbeta-transducin repeat-containing protein (β-TrCP)cancer therapydrug target

More Related Videos

Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions
10:26

Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions

Published on: December 20, 2017

9.5K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

6.9K

Related Experiment Videos

Last Updated: Jul 16, 2025

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
03:37

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

798
Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions
10:26

Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions

Published on: December 20, 2017

9.5K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

6.9K

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biochemistry

Background:

  • Beta-transducin repeat-containing proteins (β-TrCPs) are E3 ubiquitin ligases crucial for proteasomal degradation.
  • β-TrCP substrates' degradation impacts cell cycle, apoptosis, and DNA damage response.
  • β-TrCPs also regulate transcription and stabilize specific substrates via distinct mechanisms.

Purpose of the Study:

  • To review the regulatory mechanisms of β-TrCPs themselves.
  • To identify knowledge gaps in understanding β-TrCP regulation.
  • To inform future strategies for modulating β-TrCP activity.

Main Methods:

  • Literature review of publications on β-TrCP regulation.
  • Analysis of existing studies on β-TrCPs' roles in cellular processes.
  • Identification of research gaps concerning β-TrCP regulation.

Main Results:

  • β-TrCPs play critical roles in diverse cellular functions.
  • Dysregulation of β-TrCPs is associated with tumorigenesis and cancer progression.
  • Current understanding of β-TrCP regulatory mechanisms is limited.

Conclusions:

  • Further research into β-TrCP regulation is essential.
  • Understanding these mechanisms could lead to novel cancer therapies.
  • Modulating β-TrCP activity holds therapeutic potential for cancer treatment.